Table 4.
DHA supplementation vs Control at week 24.
| Control (n=21) | DHA (n=27) | Nonparametric ANCOVA* | ||
|---|---|---|---|---|
| Median (IQR) | Median (IQR) | Difference (95% CI) | p-value | |
|
| ||||
| Omega-6 fatty acids and oxylipins | ||||
| LA** | 7.3 (4.1, 9.9) | 7.6 (4.8, 11) | .64 (−1.1, 2.6) | .50 |
| 9-HODE | 3.4 (1.3, 7.9) | 2.6 (1.1, 6.2) | −.58 (−4.7, 4.4) | .78 |
| 13-HODE | 7.6 (5, 21) | 5.6 (2.6, 13) | −1.3 (−11, 8.3) | .77 |
| 9,10-DiHOME | 1.6 (1.1, 4.3) | 1.3 (.64, 4.1) | .39 (−2, 2.9) | .74 |
| 13H-9,10E-LA | .22 (.16, .36) | .19 (.12, .31) | −.029 (−.22, .18) | .77 |
| 9H-12,13E-LA | .16 (.12, .24) | .1 (.075, .28) | .028 (−.19, .26) | .80 |
| 9,12,13-TriHOME | .14 (.098, .17) | .11 (.086, .17) | −.021 (−.089, .041) | .53 |
| GLA | .049 (.036, .074) | .05 (.028, .075) | −.000018 (−.018, .016) | .99 |
| DGLA | .094 (.077, .11) | .098 (.082, .12) | .016 (−.00089, .031) | .052 |
| AA | .14 (.12, .17) | .18 (.13, .21) | .037 (.015, .062) | .002 |
| 5-HETE | .16 (.12, .17) | .14 (.12, .19) | .02 (−.052, .098) | .58 |
| 12-HETE | .088 (.08, .12) | .17 (.1, .23) | .071 (.0082, .13) | .036 |
| 15-HETE | .21 (.17, .22) | .19 (.12, .32) | .023 (−.055, .1) | .55 |
| TxB2 | .053 (.039, .11) | .057 (.036, .14) | .011 (−.051, .069) | .73 |
| DTA | .035 (.028, .048) | .035 (.028, .048) | .0051 (−.0038, .013) | .25 |
| DPA n-6 | .044 (.036, .05) | .054 (.042, .085) | .024 (.013, .037) | <0.001 |
| Omega-3 fatty acids and oxylipins | ||||
| ALA | .26 (.18, .51) | .29 (.18, .51) | .021 (−.1, .13) | .71 |
| SDA (18:4 n-3) | .0058 (.0045, .0093) | .0079 (.004, .014) | .0013 (−.0019, .004) | .40 |
| ETA (20:4 n-3) | .012 (.0089, .014) | .014 (.011, .019) | .0025 (−.0013, .0055) | .16 |
| EPA | .083 (.056, .099) | .14 (.11, .19) | .072 (.049, .099) | <0.001 |
| DPA n-3 | .023 (.016, .032) | .031 (.022, .04) | .008 (−.00029, .015) | .035 |
| DHA | .54 (.4, .78) | 1.1 (.84, 1.6) | .56 (.36, .78) | <0.001 |
| 4-HDHA | .05 (.03, .076) | .12 (.069, .17) | .099 (.011, .21) | .048 |
| 10-HDHA | .019 (.014, .038) | .034 (.021, .072) | .019 (.0037, .036) | .010 |
| 14-HDHA | .078 (.059, .12) | .2 (.12, .31) | .12 (−.0085, .25) | .06 |
| 17-HDHA | .12 (.1, .19) | .21 (.15, .28) | .019 (−.15, .16) | .81 |
| 19,20-EpDPA | .034 (.019, .063) | .077 (.057, .11) | .033 (.01, .055) | .002 |
| Other | ||||
| Mead | .011 (.007, .013) | .009 (.006, .016) | .0028 (−.0005, .006) | .09 |
*
Difference is estimated using a nonparametric ANCOVA controlling for the mediator at Week 14. A negative difference means the DHA group had a lower concentration than the control group.
**
9,10-EpOME & 9,10,13-TriHOME had >50% values below LOQ. Concentrations: fatty acids (ug/mL); oxylipins (ng/mL).